Company Analysis
Sign in

Zymeworks Inc. (ZYME)

Nasdaq: ZYME · Pharmaceutical Preparations · Middletown, DE · filing with the SEC since 2022
Full chart Alerts Compare
Grade5.1
◀ Past 5.8● Present 5.1▶ Future 4.4
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

17 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Zymeworks Inc.’s names, not what it holds today.

Patents granted
17
17 utility, 1976 to Dec 31, 2025
Granted in 2025
9
Against 6 in 2024 and 2 in 2023
Applications published
33
16 of them in 2025
Names they are printed under
2
a subsidiary
By yearGrantedApplications published
'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals9
Biotechnology5
Organic fine chemistry2
Analysis of biological materials1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
ZYMEWORKS BC INC. a subsidiary
named as the applicant on its applications, in CA
0 granted
32 published
Zymeworks BC Inc. a subsidiary
CA, as the owner printed on each patent
17 granted
1 published
Names not counted (2)
Zymeworks Inc.
Most of its patents print CA; this name counts in US. 0 granted and 92 published under it are not counted.
Zymeworks Inc.
Most of its patents print CA; this name counts in US. 56 granted and 20 published under it are not counted.
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Oct 7, 202512,435,157Methods of using a bispecific antigen-binding construct targeting HER2 for the treatment of biliary tract cancersPharmaceuticalsZymeworks BC Inc.
Oct 7, 202512,433,952Antibody-drug conjugates targeting folate receptor alpha and methods of usePharmaceuticalsZymeworks BC Inc.
Jul 15, 202512,357,701Anti-HER2 biparatopic antibody-drug conjugates and methods of usePharmaceuticalsZymeworks BC Inc.
May 20, 202512,304,954Multivalent and bispecific antibody constructs and methods of use thereofBiotechnologyZymeworks BC Inc.
May 20, 202512,304,945Engineered immunoglobulin heavy chain-light chain pairs and uses thereofBiotechnologyZymeworks BC Inc.
May 20, 202512,303,544Cytotoxic and anti-mitotic compounds, and methods of using the sameOrganic fine chemistryZymeworks BC Inc.
Apr 29, 202512,286,489Modified antigen binding polypeptide constructs and uses thereofBiotechnologyZymeworks BC Inc.
Feb 18, 202512,227,591Antigen-binding constructs targeting HER2Analysis of biological materialsZymeworks BC Inc.
Feb 4, 202512,215,166Bispecific antigen binding constructs targeting HER2PharmaceuticalsZymeworks BC Inc.
Dec 3, 202412,157,775Methods of using bispecific antigen-binding constructs targeting HER2PharmaceuticalsZymeworks BC Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Nov 6, 20252025/0339552ANTIBODY-DRUG CONJUGATES TARGETING FOLATE RECEPTOR ALPHA AND METHODS OF USEPharmaceuticalsZYMEWORKS BC INC.
Sep 25, 20252025/0295799ANTIBODY-DRUG CONJUGATES TARGETING GLYPICAN-3 AND METHODS OF USEPharmaceuticalsZYMEWORKS BC INC.
Sep 4, 20252025/0277030ANTI-NAPI2B ANTIBODIES AND METHODS OF USEPharmaceuticalsZYMEWORKS BC INC.
Jul 24, 20252025/0235548ANTIBODY-DRUG CONJUGATES TARGETING NAPI2B AND METHODS OF USEPharmaceuticalsZYMEWORKS BC INC.
Jul 10, 20252025/0222128ANTIBODY DRUG-CONJUGATES TARGETING C-MET AND METHODS OF USE THEREOFBiotechnologyZYMEWORKS BC INC.
Jul 3, 20252025/0215115MODIFIED ANTIGEN BINDINGPOLYPEPTIDE CONSTRUCTS AND USES THEREOFBiotechnologyZYMEWORKS BC INC.
Jun 19, 20252025/0197527STABLE HETERODIMERIC ANTIBODY DESIGN WITH MUTATIONS IN THE Fc DOMAINBiotechnologyZYMEWORKS BC INC.
Jun 5, 20252025/0179088IMIDAZOTHIENOPYRIDINE COMPOUNDS AND METHODS OF USEPharmaceuticalsZYMEWORKS BC INC.
May 29, 20252025/0170266IMMUNOMODULATOR PURINE-DERIVED COMPOUNDS, CONJUGATES THEREOF, AND METHODS OF USE THEREOFPharmaceuticalsZYMEWORKS BC INC.
May 1, 20252025/0136714METHODS OF TREATING CANCER WITH ANTI-HER2 BIPARATOPIC ANTIBODIESPharmaceuticalsZYMEWORKS BC INC.
What it applied for, 2024 to 2025: Pharmaceuticals 15 · Biotechnology 12 · Computer technology 2.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton ZYME · research, not advice